Advisories November 10, 2026

Environmental, Land Use & Natural Resources Advisory | California Proposes Adding Three PFAS to Proposition 65 List

Executive Summary
Minute Read

California’s proposed PFAS listings heighten compliance and enforcement concerns. Our Environmental, Land Use & Natural Resources Group explores how warning obligations would depend on product-specific exposure, not on chemical detection alone.

  • The proposals cover PFBA, PFHxA, PFDA, and related salts, so reviews limited to parent compounds or intentionally added PFAS may miss relevant substances
  • Scientifically valid data not considered by the U.S. Environmental Protection Agency may be particularly relevant to challenging the proposed listings’ scientific basis or scope
  • Comments on the proposals are due to the Office of Environmental Health Hazard Assessment on November 30, 2026

California’s Office of Environmental Health Hazard Assessment (OEHHA) has proposed adding three per- and polyfluoroalkyl substances (PFAS), and certain related salts, to the Proposition 65 list of chemicals known to the state to cause reproductive toxicity: perfluorobutanoic acid (PFBA), perfluorohexanoic acid (PFHxA), and perfluorodecanoic acid (PFDA). The proposals, issued October 30, 2026, rely on toxicity determinations by the U.S. Environmental Protection Agency (EPA) and invoke Proposition 65's "authoritative bodies" listing mechanism. Public comments are due November 30, 2026.

Before any final listing, companies that manufacture, distribute, import, or sell products containing these PFAS should determine whether the substances are present in their products or supply chains, evaluate potential exposure pathways, and identify whether the scientific record provides a basis for comments on the proposed listings.

Proposition 65

Proposition 65 requires California to maintain and update a list of chemicals known to cause cancer, birth defects, or other reproductive harm. Businesses that expose individuals to listed chemicals must provide a "clear and reasonable" warning unless an affirmative defense applies. For example, a business has an affirmative defense if it can demonstrate that the anticipated exposure level poses no significant risk of cancer (for carcinogens) or will have no observable effect (for reproductive toxicants).

Proposition 65 is enforced primarily through private actions. Before filing a lawsuit, a private plaintiff must serve a 60-day notice of violation on the alleged violator, the California Attorney General's Office, and applicable district attorneys and city attorneys. That 60-day period allows the business to correct the alleged violation, negotiate a settlement, or prepare a defense. If no public enforcement action is initiated within 60 days, the private plaintiff may proceed with litigation seeking injunctive relief, civil penalties of up to $2,500 per day per violation, and recovery of attorneys' fees.

Three PFAS Already Listed

Three types of PFAS are already listed under Proposition 65: PFOS (listed in 2017), PFOA (listed in 2017), and PFNA and its salts (listed in 2021).

Private enforcers have served nearly 1,000 Proposition 65 notices of violation for these chemicals—covering everything from mineral water to cosmetics, and dietary supplements to apparel. Almost 30 of the notices have involved alleged discharges of these chemicals into sources of drinking water.

Three More PFAS Could Join the Proposition 65 List

OEHHA’s three notices of intent would add:

  • PFBA (CAS No. 375-22-4) and related salts, based on developmental, male reproductive, and female reproductive endpoints.
  • PFHxA (CAS No. 307-24-4) and related salts, based on a developmental endpoint.
  • PFDA (CAS No. 335-76-2) and related salts, based on developmental, male reproductive, and female reproductive endpoints.

The scope of the proposals extends beyond the three acids themselves. Each notice encompasses specified salts and other nonmetal or alkali-metal salts that may dissociate under physiological conditions. That distinction could matter for companies assessing chemical inventories and supplier information because a review focused solely on the CAS number for the parent acid may not capture all substances within OEHHA's proposed listing.

The notices also illustrate the breadth of potential sources. OEHHA describes PFAS as widely used because of their heat-, oil-, stain-, and water-resistant properties. The PFDA notice specifically cites reported detection in cosmetics, outdoor textiles, carpet, ski wax, and leather. OEHHA identifies PFHxA as a metabolite and degradation product of fluorotelomer-based chemicals, including 6:2 fluorotelomer alcohol, while its PFBA notice states that PFBA is a breakdown product of other PFAS.

The "Authoritative Bodies" Mechanism

OEHHA is not undertaking an independent hazard-identification process from scratch. Instead, it is invoking Proposition 65's authoritative bodies mechanism under Health and Safety Code Section 25249.8(b) and California Code of Regulations, Title 27, Section 25306. The EPA is one of the bodies designated under California's regulations as authoritative for identifying chemicals that cause reproductive toxicity.

Under that mechanism, OEHHA must list a chemical when an authoritative body has formally identified it as causing reproductive toxicity and the evidence considered by that body satisfies California’s regulatory sufficiency criteria. Importantly, however, the regulations also provide that a chemical is not listed if scientifically valid data not considered by the authoritative body clearly establish that the sufficiency-of-evidence criteria were not met.

That framework makes the scientific bases for the three proposed listings particularly important.

For PFHxA, OEHHA relies on the EPA's 2023 toxicological review and its conclusion that PFHxA "likely causes developmental effects in humans." The EPA established chronic and subchronic oral reference doses based on decreased offspring body weight, and OEHHA concluded that this evidence satisfies Proposition 65’s criteria for a reproductive-toxicity listing based on a developmental endpoint.

For PFDA, OEHHA relies on the EPA's 2024 toxicological review concluding that PFDA is likely to cause developmental, male reproductive, and female reproductive effects, among other effects, in humans. The purported developmental evidence includes animal studies involving decreases in fetal weight as well as epidemiological evidence involving birth and childhood weight. OEHHA also cites purported evidence concerning sperm counts, testosterone levels, and reproductive effects in animal studies.

The record is nuanced for PFBA. OEHHA cites EPA findings of developmental effects, including delayed developmental milestones following gestational exposure. But the EPA also concluded that there was "inadequate evidence" to determine whether PFBA exposure has the potential to cause reproductive toxicity in adults. OEHHA nevertheless concluded that the developmental effects involving reproductive developmental landmarks support listing based on developmental, male reproductive, and female reproductive endpoints.

That distinction may warrant particular attention from stakeholders evaluating whether to comment on the scope or scientific basis of the PFBA proposal.

Why the Proposed Listings Matter

A Proposition 65 chemical listing does not automatically mean that every product containing a listed PFAS must carry a warning. Proposition 65’s warning requirement turns on exposure, not simply the presence of a listed chemical.

That distinction is particularly important for PFAS. Businesses should avoid equating analytical detection of PFBA, PFHxA, or PFDA with a conclusion that a Proposition 65 warning will be required. Whether a warning obligation ultimately arises can depend on the nature and concentration of the chemical, reasonably anticipated use of the product, routes and levels of exposure, regulatory safe harbor levels (if adopted), and other product-specific factors.

At the same time, listing can have consequences well before a private enforcement action is filed. For companies with potentially affected products, it can trigger questions about supply chain data, laboratory testing, exposure assessments, and contractual allocation of compliance obligations and liability.

The proposals are also notable because OEHHA is addressing three PFAS at once through the same regulatory mechanism, underscoring the increasingly important intersection between PFAS regulation and California’s private-enforcement regime.

What Companies Should Do Now

Companies that manufacture, distribute, import, or sell products in California should take several steps:

  1. Decide whether to participate in the comment process. Because OEHHA is proceeding through the authoritative bodies mechanism, comments on the regulatory criteria and scientific record may be especially relevant. The regulation expressly contemplates scientifically valid data not considered by the authoritative body that may establish that the sufficiency criteria were not met. Businesses possessing relevant toxicological or other scientific information should consider whether that information bears on OEHHA's analysis.
  2. Preserve the distinction between hazard identification and exposure assessment. The EPA's toxicological determinations and OEHHA's proposed listings address hazard identification. They do not, standing alone, establish that a particular consumer exposure requires a Proposition 65 warning. Maintaining that distinction will be important as companies evaluate compliance options and potential enforcement risk.
  3. Determine whether PFBA, PFHxA, PFDA, or covered salts may be present. A targeted review should consider more than intentionally added PFAS. OEHHA describes PFBA as a breakdown product of other PFAS and PFHxA as a metabolite and degradation product of fluorotelomer-based chemicals. Accordingly, supplier declarations directed only at intentionally added PFAS may not answer the entire question.
  4. Review supplier and testing data with the proposed listing language in mind.
    Because the proposals extend to specified “related salts,” companies should confirm that chemical-inventory and analytical reviews encompass the particular substances covered by OEHHA's proposed definitions rather than searching only for the three parent compounds.
  5. Do not assume detection equals a warning obligation. If testing identifies one of the proposed chemicals, the next question should generally be whether foreseeable use of the product results in an exposure that would trigger the Proposition 65 warning requirement, rather than treating chemical presence alone as conclusive. This analysis usually requires coordination with a toxicologist to perform an exposure assessment.

What’s Next

Comments on all three proposed listings must be submitted to OEHHA by Monday, November 30, 2026. OEHHA's notices specifically invite comments on whether the chemicals satisfy the criteria for listing under the authoritative bodies mechanism.

For companies with potentially affected products, the immediate priority is to understand whether these chemicals or covered salts are present, determine whether meaningful consumer or occupational exposures could occur, and evaluate whether there is scientific information relevant to OEHHA's proposed determinations before the comment period closes.

The broader takeaway is equally important: Detection of PFAS does not necessarily mean a business must display a Proposition 65 warning. If these chemicals are ultimately listed, companies will need to assess exposure on a product-specific basis rather than treating analytical detection alone as determinative.


If you have any questions, or would like additional information, please contact one of the attorneys on our Environmental, Land Use & Natural Resources team.

You can subscribe to future advisories and other Alston & Bird publications by completing our publications subscription form.


Meet the Author
Media Contact
Alex Wolfe
Communications Director